Abstract:Importance: Recent reports based on the US Food and Drug Administration's voluntary Adverse Events Reporting System raised questions about the safety of direct-acting antivirals (DAAs) for treatment of the hepatitis C virus (HCV). Objective: To assess the rates of adverse events in patients with HCV infection exposed to DAAs compared with those not exposed. Design, setting, and participants: A retrospective cohort study calculated unadjusted adverse event rates for exposed vs unexposed time, using claims and clinical data from 3 health systems between January 1, 2012, and December 31, 2017. Of 82 419 eligible adults, a total of 33 808 who met eligibility criteria (age, 18-88 years; HCV quantitative result or genotype from 2012 or later; continuously enrolled; naive to DAA treatment at baseline) were included. Marginal structural modeling methods were used to adjust time-to-event analyses for characteristics that are associated with both outcomes and probability of treatment. Interventions or exposures: Exposure to DAAs compared with no DAA exposure. Main outcomes and measures: Death, multiple organ failure, liver cancer, hepatic decompensation, acute-on-chronic liver event, acute myocardial infarction, ischemic or hemorrhagic stroke, arrhythmia, acute kidney failure, nonliver cancer, hepatitis B reactivation, hospitalizations, and emergency department visits. Results: Of the 33 808 patients who met all inclusion criteria, 20 899 (61.8%) were men; mean (SD) age was 57.2 (10.6) years. In unadjusted analyses, DAA exposure was associated with significantly lower rates of death (10.7 vs 33.7 events per 1000 person-years; rate ratio [RR], 0.32, 95% CI, 0.25-0.40). Seven other unadjusted adverse clinical events ratios were below 70% and statistically significant favoring the DAA group: multiple organ failure (RR, 0.56; 95% CI, 0.44-0.72), liver cancer (RR, 0.62; 95% CI, 0.48-0.80), hepatic decompensation (RR, 0.62; 95% CI, 0.52-0.73), acute-on-chronic liver event (RR, 0.68; 95% CI, 0.56-0.84), acute myocardial infarction (RR, 0.64; 95% CI, 0.42-0.97), ischemic stroke (RR, 0.63; 95% CI, 0.42-0.95), and hemorrhagic stroke (RR, 0.47; 95% CI, 0.25-0.89); none favored the non-DAA group. In the marginal structural modeling-adjusted analysis, DAA exposure was associated with statistically significant lower odds of adverse events than non-DAA exposure for death (adjusted odds ratio [aOR], 0.42; 95% CI, 0.30-0.59), multiple organ failure (aOR, 0.67; 95% CI, 0.49-0.90), hepatic decompensation (aOR, 0.61; 95% CI, 0.49-0.76), acute-on-chronic liver event (aOR, 0.71; 95% CI, 0.56-0.91), and arrhythmia (aOR, 0.47; 95% CI, 0.25-0.88). Conclusions and relevance: Direct-acting antiviral exposure may not be associated with higher rates of any serious adverse events, including those related to liver, kidney, and cardiovascular systems. Safety concerns based on previous reports did not appear to be supported in this study with more comprehensive data and rigorous statistical methods.

No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.

Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Clinical Benefits of Direct‐acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis

Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma

Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy

Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon Versus Direct-Acting Agents

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy

Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection

Hepatitis B Reactivation in Patients Receiving Direct-Acting Antiviral Therapy or Interferon-Based Therapy for Hepatitis C: A Systematic Review and Meta-Analysis

DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C

Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals

Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis

Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis

Prognosis and incidence of immunological and oncological complications after direct-acting antiviral therapy for chronic hepatitis C

Sustained Virologic Response to Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Association between Direct Acting Agents used for chronic hepatitis C virus infection and the occurrence of acute leukaemia – A disproportionality analysis

Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C